CLRB Overview

Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of drugs for treatment of cancer. The Company, through its phospholipid ether drug conjugate (PDC) delivery platform, is focused on developing PDCs that are designed to specifically target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs both independently and through research and development collaborations. Its lead programs are: Iopofosine I 131 (iopofosine), a beta-emitting iodine-131-based program which has been studied extensively; CLR 121225, an actinium-225-based program; and CLR 121125, an iodine-125 Auger-emitting program. Iopofosine evaluation is ongoing in a Phase IIb study in r/r multiple myeloma and central nervous system lymphoma patients and the CLOVER-2 Phase Ib study for pediatric patients with high grade gliomas.

Wall Street analysts forecast CLRB stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLRB is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Cellectar Biosciences Inc revenue for the last quarter amounts to -5.69M USD, decreased -55.35

Cellectar Biosciences Inc. EPS for the last quarter amounts to -4350016.00 USD, decreased -60.36

Cellectar Biosciences Inc (CLRB) has 11 emplpoyees as of March 10 2026.

Today CLRB has the market capitalization of 12.93M USD.